Abstract: The KAI1 protein or a fragment thereof according to the present invention inhibited hepatic fibrosis in mice in which acute hepatic fibrosis was induced by CCl4. The KAI1 protein suppressed hepatic fibrosis by inhibiting fibrosis of hepatocytes treated with TGF-?1 and promoting senescence of hepatic stellate cells. Therefore, the pharmaceutical composition comprising the KAI1 protein according to the present invention may be used to effectively prevent or treat hepatic fibrosis.

Abstract: Provided are a composition including a Kang AI 1 (KAI1) polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.

Abstract: The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.

Abstract: Provided is a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1h, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.

Abstract: Provided is a KAI1 protein controlling the cell cycle of a hematopoietic stem cell and a use thereof, and more specifically, a composition including a KAI1(CD82) polypeptide or a gene encoding the same for controlling the cell cycle of a hematopoietic stem cell, or a pharmaceutical composition for preventing or treating blood tumors. Further provided, KAI1(CD82) is expressed only in a hematopoietic stem cell (LT-HSC) which is the uppermost stem cell in the hierarchy of the hematopoietic stem cell, can obtain an LT-HSC with high purity using the KAI1, and thus can inhibit various side effects of hematopoietic stem cell transplantation by transplanting only an LT-HSC with high purity. In addition, KAI1 importantly acts on the quiescence of an LT-HSC, and has resistance against cell damage due to various stresses (5-FU, irradiation, etc.) by maintaining the quiescence of the LT-HSC.

Abstract: A stator of a switched reluctance motor includes a stator core part, stator coiling parts, stator salient parts, and pairs of permanent magnets. The stator coiling parts protrude inwardly from the stator core part and have coils wound on an external side thereof. The stator salient parts protrude inwardly from the stator core part and are disposed between the stator coiling parts. Each pair of the permanent magnets is inserted into each of the stator coiling parts and magnetized in the same direction as a direction of a magnetic field generated by the excitation of the coils. This stator has an electromagnetic structure designed to prevent the reversal of a magnetic field generated by the excited coils. The output of the motor is enhanced by inserting the permanent magnets so as to be magnetized in the same direction as a direction of a magnetic field generated by the excited coils.

Abstract: The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.

Abstract: There are provided a pharmaceutical composition for treating immune-related diseases, a pharmaceutical composition for treating ischemic diseases, a pharmaceutical composition for promoting lymphangiogenesis, a pharmaceutical composition for treating neurological diseases, a pharmaceutical composition for treating metabolic diseases, and the like, which contain blood-born hematospheres, and more specifically, may differentiate into inflammatory mononuclear cells, vascular endothelial cells, vascular smooth muscle cells, lymphatic vessel adult stem cells and progenitor cells, neural progenitor cells and nerve cells, insulin secreting cells, and the like by effective 3D culturing using blood mononuclear cells. Therefore, the present invention is expected to be used for development of a cell therapeutic agent for various types of diseases.

Abstract: The present invention relates to a technique of using monocytic blood cells to effectively culture and proliferate blood adult stem cells and progenitor cells that only exist in small quantities to effectively obtain large quantities of stem cells. According to the present invention, the limitation of being able to derive only small quantities of stem cells from blood can be overcome, and the pluripotency of stem cells can easily be obtained.

Abstract: A stator of a switched reluctance motor includes a stator core part, stator coiling parts, stator salient parts, and pairs of permanent magnets. The stator coiling parts protrude inwardly from the stator core part and have coils wound on an external side thereof. The stator salient parts protrude inwardly from the stator core part and are disposed between the stator coiling parts. Each pair of the permanent magnets is inserted into each of the stator coiling parts and magnetized in the same direction as a direction of a magnetic field generated by the excitation of the coils. This stator has an electromagnetic structure designed to prevent the reversal of a magnetic field generated by the excited coils. The output of the motor is enhanced by inserting the permanent magnets so as to be magnetized in the same direction as a direction of a magnetic field generated by the excited coils.

Abstract: The present invention relates to a technique of using monocytic blood cells to effectively culture and proliferate blood adult stem cells and progenitor cells that only exist in small quantities to effectively obtain large quantities of stem cells. According to the present invention, the limitation of being able to derive only small quantities of stem cells from blood can be overcome, and the pluripotency of stem cells can easily be obtained.

Abstract: A method and apparatus for manufacturing a tonewheel for vehicles. The method includes machining a material into a tonewheel shape, manufacturing a semi-finished tonewheel product having a sensing part in which a plurality of sensing holes is formed at regular intervals in a circumferential direction of the sensing part, by machining the tonewheel shape manufactured at the forming step, and manufacturing a finished tonewheel product having a sensing part of which deformation is recovered, by processing the sensing part of the semi-finished tonewheel product, which is deformed to be curved at the sensing-hole machining step, through a restrike mold. The apparatus is capable of performing the method.

Abstract: A claw-pole PM stepping motor includes a module that is formed in such a manner that a first driving unit and a second driving unit are symmetrically arranged with respect to a first claw-pole and a second claw-pole each oppositely disposed at a main yoke member internally disposed to substantially divide an inside of a housing, an inner portion of which is rotatably inserted and supported by a rotary shaft, and the first driving unit and the second driving unit have magnet rotors coaxially arranged to generate electromagnetic force; sub-yoke members; and coil bobbins. The claw-pole PM stepping motor is exempted from a structure where coil bobbins are concentrically arranged at a periphery of magnet rotors, and instead the coil bobbins are coaxially arranged and shifted from each other from the corresponding magnet rotors, such that a miniaturized motor with a reduced outer diameter can be embodied.

Abstract: Disclosed herein is a method and apparatus for manufacturing a tonewheel for vehicles. The present invention is capable of manufacturing a tonewheel having high precision and quality, thus enhancing the performance of the ABS, TCS, or VDC using the tonewheel.

Abstract: A claw-pole PM stepping motor includes a module that is formed in such a manner that a first motor assembly and a second motor assembly are symmetrically arranged with respect to a first claw-pole and a second claw-pole each oppositely disposed at a main yoke member internally disposed to substantially divide an inside of a housing, an inner portion of which is rotatably inserted and supported by a rotary shaft, and the first motor assembly and the second motor assembly have magnet rotors coaxially arranged to generate electromagnetic force; sub-yoke members; and coil bobbins. The claw-pole PM stepping motor is exempted from a structure where coil bobbins are concentrically arranged at a periphery of magnet rotors, and instead the coil bobbins are coaxially arranged and shifted from each other from the corresponding magnet rotors, such that a miniaturized motor with a reduced outer diameter can be embodied.

Abstract: An apparatus for painting the door of a vehicle comprising a painting robot having a door open/close jig, including a supporting bar elastically supported by a spring and a permanent magnet; and a holding unit for a door panel having a height control cylinder for controlling the height thereof, a moving cylinder for holding or releasing the door opened, a rotor connected with the moving cylinder, and a guide shaft mounted on an end of the rotor and having a holder provided a plurality of recesses for holding the door panel on its surface. The apparatus does not require a separate door open/close robot that is expensive and the revising work during the painting process.